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Abstract 
 
Methamphetamine (METH) is a potent psychostimulant highly used worldwide.  Recent 
studies evidenced the involvement of METH in the breakdown of the blood-brain-barrier 
(BBB) integrity leading to compromised function. The involvement of the matrix 
metalloproteinases (MMPs) in the degradation of the neurovascular matrix components and 
tight junctions (TJs) is one of the most recent findings in METH-induced toxicity. As BBB 
dysfunction is a pathological feature of many neurological conditions, unveiling new 
protective   agents   in   this   field   is   of   major   relevance.   Acetyl- L-carnitine (ALC) 
has been described to protect the BBB function in different paradigms, but the mechanisms 
underlying its action remain mostly unknown. Here, the immortalized bEnd.3 cell line was 
used to evaluate t h e  n e u r o p r o t e c t i v e    features o f  A L C  i n  M E T H -induced damage. 
Cells were exposed to ranging concentrations of METH, and the protective effect of ALC 
1 mM was assessed 24 h after treatment. F-actin rearrangement, TJ expression and 
distribution, and MMPs activity w e r e  e v a l u a t e d .  Integrin-linked   kinase ( ILK) 
k n o c k d o w n  cells    were    used   to   assess    role   of   ALC    in   ILK   mediated 
METH-triggered MMPs’ activity. Our results show that METH led to disruption of the actin 
filaments concomitant with claudin-5 translocation   to t h e  c y t o p l a s m .   These e v e n t s  
w e r e  m e d i a t e d    by MMP-9 activation in association with ILK overexpression. 
Pretreatment   with   ALC   prevented   METH-induced   activation   of MMP-9, preserving 
claudin-5 location and the structural arrangement of the actin filaments.  The present results 
support the potential of ALC in preserving BBB integrity, highlighting ILK as a new target 
for the ALC therapeutic use. 
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Introduction 
 
Methamphetamine (METH) is a powerful psychostimulant with high abuse liability. Both 
short- and long-term METH uses lead to long-lasting deleterious effects [1, 2]. METH 
toxicity is typically characterized by disruption of synaptic integrity and decreased 
monoamine production [3 – 5], concomitant with terminal degeneration and neuronal death 
[2, 6]. METH is increasingly recognized to impact also non-neuronal cells, such as microglia, 
and astrocytes and the blood-brain-barrier (BBB), causing the release of inflammatory 
  
mediators and astrogliosis [1, 3, 7, 8]. The concept of METH-induced damage at the level of 
the BBB has gained relevance over the last few years, justifying the interest in understanding 
its consequences at the endothelium [4, 9, 10]. 
 
 
METH-induced permeability at the BBB has been consistently reported both in vivo and in 
vitro [4, 5, 11]. In mice models, METH was seen to increase permeability and induce massive 
leakage of macromolecules across the BBB in the cerebral cortex, hippocampus, and other 
limbic regions [5, 6, 9]. In vitro, BBB increased permeability after METH exposure was 
accompanied by a reduction and/or redistribution of the tight junction (TJ) proteins [7, 12 – 
14]. 
 
 
The BBB is part of the neurovascular unit and is responsible for maintaining a homeostatic 
microenvironment for the central nervous system (CNS). Although pericytes, astrocytes, 
and the surrounding basement membrane play a structural and regulatory role on the 
neurovascular unit, the endothelial cells (ECs) are the barrier-conferring properties of the 
BBB [13, 15 – 17]. Its modulation is essentially a function of the TJ proteins [13, 16, 18 – 20]. 
Claudins, essentially claudin-5, ensure the tightness of the contact between the brain 
capillaries ECs, which is critical in determining BBB permeability [21, 22], while occludin 
plays a regulatory role and enhances TJ tightness [18]. The endothelial paracellular 
permeability occurs due to the equilibrium between cytoskeleton contractile forces and 
adhesive forces produced at the endothelial cell-cell junctions and cell-matrix contacts [14], 
where actin filaments play an essential role. Functioning as a cross-linker between occludin 
and the actin cytoskeleton, the protein ZO-1 is also central to the TJ structure [10, 13, 18, 
23]. 
 
 
BBB impairment with TJ dysfunction is a hallmark of many pathological states such as 
inflammation, tumor differentiation [24], epilepsy, Parkinson’s and Alzheimer’s disease, 
multiple sclerosis, and ischemia/reperfusion [25]. Importantly, METH-induced BBB 
increased permeability was associated with reduction and/or redistribution of TJ proteins [10, 
13]. There is also evidence that it can interfere with structure and arrangement, which also 
may lead to compromised TJ function [14, 26]. Although the molecular mechanisms 
underlying BBB disruption under METH exposure are not fully characterized, the activation 
of matrix metalloproteinases (MMPs), commonly involved in remodeling and degradation 
of the neurovascular matrix components and therefore associated with BBB leakiness, has 
been reported [ 4 , 6 , 9 , 27 ]. 
 
 
Investigating the mechanisms that underlie the action of compounds able to counteract these 
detrimental effects at the level of BBB is of major relevance. Acetyl-L-carnitine (ALC) has 
been described to protect the BBB function from EtOH-induced inhibition of glucose 
transport [28] and increased reactive oxygen species (ROS) levels [29]. ALC is a natural 
occurring compound synthesized from acetyl-CoA and carnitine [30 – 32], able to cross the 
BBB, essentially through organic cation transport (OCTN2) [33 – 35], and reaching high 
concentrations in the brain [30, 34]. When therapeutically administered, ALC is more easily 
transported across the BBB than L-carnitine, which supports its prescription in acute and 
  
chronic neurological disorders [ 34 ]. ALC described effects include the modulation of 
neurotrophic factors and multiple neurotransmitters, as well as mitochondrial stabilization 
[ 30 , 31 ], but the mechanisms involved in its action at the BBB level remain elusive. 
 
Here, we used a model of endothelial cells exposed to ranging doses of METH to evaluate 
the potential protective role of ALC. Based on former reports [ 28 , 36 ], we hypothesized 
that ALC could be protective at the BBB level by counteracting the effect of METH in the 
structural disruption of TJ and consequential loss of adhesive forces. We further 
hypothesized that ALC could be protective by preventing METH-triggered activation of 
MMPs. 
 
 
Material and Methods 
 
In Vitro Model and Cell Culture 
 
The immortalized bEnd.3 cells are derived from mouse brains and known to mimic some of 
the BBB characteristics [ 37 , 38 ]. The cell line bEnd.3 was obtained from ATCC (American 
Type Cell Culture-CRL-2299, Manassas, VA), and cultures were maintained in Dulbecco’s 
Modified Eagle’s medium (DMEM) (1×)/Glutamax (GIBCO®, Life Technologies, Paisley, 
UK), containing 5 % penicillin and streptomycin (GIBCO®, Life Technologies) and 10 % 
fetal bovine serum (GIBCO®, Life Technologies). Purity of the cell line was checked using 
an anti-CD31 antibody (Abcam 7388, rat monoclonal, 1:1000), which showed 100 % 
enrichment of cells on the adhesion marker. For viability assays, cells were cultured in 24-
well plates (80,000 cells/well). For immunofluorescence, cells were plated on 24-well plates 
(80,000 cells/well) containing glass cover slips. To obtain protein extracts, bEnd. 3 cells 
were cultured in petri dishes (one million of cells). Cell culture media was changed every 3 
days until cells were confluent. 
 
Drug Regimen 
 
ALC-hydrochloride was kindly provided by Sigma-Tau, S.p.a (Pomezia, Italy). METH 
hydrochloride was purchased from Sigma-Aldrich (St. Louis, MO, Cat.M-8750). 
 
 
Immortalized bEnd.3 cells at confluence were treated with 0.25, 0.5, and 1 mM of METH, 
with or without a pretreatment with 1 mM ALC added 30 min prior to METH. The METH 
range of doses tested was predetermined in our laboratory in agreement with previous studies 
using METH in similar cell models [39]. The selected ALC dose of 1 mM is not toxic for the 
cells and is within the range of doses previously used in similar works [40]. For zymography 
studies, cells were treated with 10 nM BB-94 (Batimastat, Tocris Bioscience, and Bristol, 
UK), a broad spectrum MMP inhibitor [41], 15 min prior to METH exposure. 
 
 
Cell Viability Assay—MTT 
 
Cell viability was determined by 3-(4,5-dimethylthiazol-2yl)-2,5- diphenyl tetrazolium 
bromide (MTT) assay, which is based on the reduction of yellow tetrazolium salt to purple 
formazan crystals by metabolically active cells. The reduction of MTT is thought to mainly 
  
occur in the mitochondria through the action of succinate dehydrogenase, therefore, 
providing a measure of mitochondrial function [42]. In these assay, METH concentrations of 
0.25, 0.5, and 1 mM were used. Briefly, 24 h after treatment, the cells were added MTT (0.5 
mg/mL, Sigma-Aldrich, Steinheim, Germany) and incubated at 37 °C. DMSO (Sigma-
Aldrich) was then added to promote the dissolution of MTT-formazan crystals. Absorbance 
of the purple formazan was measured in duplicate by a microplate reader (Sunrise Tecan™, 
Mannedorf, Switzerland) at 540-nm wavelength. 
 
 
Lactate Dehydrogenase Cytotoxic Assay 
 
At 24 h of METH exposure, the LDH release to the extracellular medium was evaluated by 
a colorimetric assay using the CytoTox96 Non-Radioactive Assay kit (Promega, Madison, 
WI), according to the manufacturer’s instructions. The percentage of LDH release was 
determined as the ratio between LDH activity in the extracellular medium and total LDH 
activity obtained after complete cell lysis with Triton X-100. All experiments were carried 
out in duplicate, using a microplate reader at 490 nm (Sunrise Tecan™). 
 
 
Immunostaining Procedure 
 
For immunocytochemistry, bEnd.3 cells were cultured on glass cover slips in 24 well plates 
until 90–100 % confluent. Cells were then treated with 0.5 and 1 mM of METH in the 
presence or absence of 1 mM ALC (added 30 min before), for 24 h. For F-actin filaments 
evaluation, cells were washed with phosphate buffered saline (PBS) and fixed with 
microtubule-protecting buffer (MPB) (65 mM PIPES; 25 mM HEPES; 10 mM EGTA; 3 
mM MgCl2) diluted in 4 % paraformaldehyde (pH 6.9), for 10 min. After permeabilization 
with Triton X-100 0.1 % for 10 min, cells were blocked with 10 % normal goat serum (NGS) 
for 45 min and incubated at room temperature for 1 h with Alexa488®-conjugated primary 
antibody (Phalloidin, Life Technologies, A12379, 1:1000). For claudin-5 and occludin, cells 
were washed with PBS, fixed during 15 min in methanol and permeabilized in 0.1 % Triton 
X-100 during 10 min. After a blocking of 45 min in 5 % BSA (bovine serum albumin), cells 
were incubated overnight at 4 °C with respective primary antibodies—Rabbit anti-Claudin-
5 (Abcam 53765, 1:200) and Rabbit anti-occludin (Invitrogen #71–1500, 5 µg/mL). For ZO-
1 immunoreaction, a preincubation with a preextraction buffer (as described by Balda MS, 
1996 [ 16 ]) was performed before 96 % ethanol fixation (30 min, on ice). Cells were 
rehydrated, permeabilized for 10 min with 0.05 % Triton X-100 and blocked for 45 min with 
10 % NGS before overnight at 4 °C incubation with primary antibody (Rabbit ZO-1, 
Invitrogen #44–2200, 2.5 µg/mL). For secondary antibody incubation, we used Anti-Rabbit 
IgG Alexa-Fluor488® Conjugate (Cell Signaling, #4412, 1:1000), for 1 h at room 
temperature in the dark. 
Coverslips were then mounted onto glass slides (Fluorescent Mounting Medium, CA, USA) 
containing 4′,6-diamidino-2-phenylindole (DAPI), and then fluorescence microphotographs 
were captured using AxioImager Z1 fluorescence microscope (Carl Zeiss, Germany). 
 
 
 
Morphometric Analysis 
  
 
F-actin Analysis 
 
Changes observed on F-actin by immunofluorescence were analyzed by the Directionality 
plugin of Fiji Software version 2.0. This plugin is used to infer the preferred orientation of 
structures present in the input image. The final result is a histogram indicating the amount 
of filaments in a given direction (from −90 to 90°), peaking at the preferred orientation. 
Measurements were obtained using the Fiji Local Gradient Orientation tool that uses a 5  ×  5 
Sobel filter to derive the local gradient orientation [adapted from 43]. To compare different 
conditions, a minimum of four independent experiments was considered and an average of 
twelve images were captured blindly. For each condition, an average histogram was built 
using the mean of the amount of filaments in each bin/orientation. To analyze differences 
in the directionality of actin filaments, we used the interval of fifteen consecutive degrees 
containing the higher number of filaments for each condition. 
 
 
Claudin-5 Analysis 
 
Analysis of claudin-5 immunofluorescence images was made using the Fiji Software version 
2.0. A total of four independent experiments were performed. From each coverslip, six 
images were blindly captured and analyzed. A straight line perpendicular to the cellular 
membrane limits was drawn for all cells within each image. This line was drawn always at 
a similar distance from the nucleus. An intensity plot profile of the line drawn was built to 
calculate the ratio between membrane and cytosol pixel intensity [adapted from 3]. The 
mean ratio of membrane/cytosol pixel intensity per condition was also calculated. 
 
 
Protein Expression Analysis by Western Blot 
 
Confluent bEnd.3 cells cultured in petri dishes were scrapped and lysed with TEN Buffer 
(50 mM Tris-HCl, 2 mM EDTA, 150 mM NaCl, 1 % NP-40, supplemented with phosphatases 
and proteases inhibitors) and then centrifuged at 14,000  ×  g for 15 min at 4 °C. Protein 
concentration of the cell lysate was estimated in the supernatant by the Bradford method 
(Bio-Rad Protein Assay, Munich, Germany). Proteins were loaded at 40 µg per lane and 
resolved by SDS-PAGE on 10 to 12 % Bis/acrilamide gels and then transferred onto PVDF 
membranes. After blocking with dry milk 5 %, membranes were incubated with rabbit 
polyclonal antibodies to claudin-5 (Abcam 53765, 1:500), occludin 
(Invitrogen #71–1500, 2 µg/mL), ZO-1 (Invitrogen #44–2200, 2 µg/mL), and mouse 
polyclonal antibody to GAPDH (glyceraldehyde-3-phosphate dehydrogenase, Hytest #5G4, 
1:300000). Secondary antibody horseradish peroxidase (HRP)-conjugated were used for 1-
h incubation. Chemiluminescence signal detection was performed using the traditional 
developer, using Immun-Star HRP (Bio-Rad Laboratories, USA). A GS800 densitometer 
(Bio-Rad) and Quantity One 1-D analysis software (v4.6, Bio-Rad) were used for 
densitometry analysis. 
 
  
 
Subcellular Fractionation 
 
Confluent monolayers were scrapped and lysed on fractionation buffer 
(250 mM sucrose, 20 mM HEPES (pH 7.4), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA and 
1 mM EGTA) supplemented with 1 mM DTT and protease inhibitor cocktail, for 20 min. 
Lysates were aspirated at least 10 times through a 25 G needle in a 1-mL syringe and left 
on ice for 20 min. A 5-min centrifugation at 720 G was performed to centrifuge out the 
nuclear pellet, and the supernatant was re-centrifuged for 5 min at 10,000 G. The membrane 
and the cytoplasmic fractions were separated by ultracentrifugation at 100.000 G for 1 h 
(ultracentrifuge Beckman Coulter, 70.1 Ti Rotor, CA, USA). The supernatant (cytoplasmic 
fraction) was collected, and the pellet obtained was washed in fractionation buffer and 
resuspended with a 25 G needle as above. The membrane fraction was re-centrifuged for45 
min, and the final pellet was resuspended in fractionation buffer supplemented with 10 % 
glycerol and 0.1 % SDS. The cytoplasmic fraction was concentrated through a filter unit 
(Amicon Ultra Centrifugal Filters, UFC501024). All steps were carried out at 4 °C. 
 
Both membrane and cytoplasmic protein concentrations were determined as described above. 
Western blot was used to analyze tight junction amount in each fraction. 
 
 
MMPs Gelatinolytic Assay 
 
Culture-conditioned media from bEnd.3 cells was collected in confluent serum-free 
monolayers from each condition for determination of MMP-2 and MMP-9 activities. The 
collected medium was centrifuged (8000 g, 5 min) to remove cell debris and applied in a 
non-reducing SDS-PAGE containing 0.1 % gelatin. The electrophoresed gels were washed 
twice for 30 min in 2 % Triton X-100 at room temperature and incubated for 16 h at 37 °C 
in the substrate buffer (50 mM Tris-HCl, pH 7.5; 10 mM CaCl2) to allow gelatin digesting 
by MMP-2 and MMP-9. After staining with 0.1 % Coomassie Brilliant Blue R-250, the gels 
were destained (in 20 % methanol and 10 % acetic acid) and the enzyme-digested regions 
were seen as clear bands against a blue background. The visualized bands were quantified 
by densitometry using GS800 densitometer and Quantity One 1-D Analysis software, v4.6. 
 
 
Transfection and ILK Silencing 
 
Integrin-linked kinase (ILK) knockdown was performed using small hairpin RNA (shRNA)-
mediated silencing technology from SIGMA (Mission shRNA). The clone 
TRCN0000022517 was used in HEK293T cells to the lentivirus production. After 48 h, 
virus was collected and frozen. For infection, bEnd.3 cells were treated for 12 h at 37 °C 
with lentivirus diluted in DMEM (1×)/Glutamax (GIBCO®, Life Technologies, Paisley, 
UK), containing 5 % penicillin and streptomycin (GIBCO®, Life Technologies) and 10 % 
fetal bovine serum (GIBCO®, Life Technologies) containing 5 µg/mL polybrene. 
Afterwards, the virus containing medium was replaced by fresh medium. Selection of 
infected cells was done with puromycin treatment (2 µg/mL). ILK silencing (KD ILK) was 
  
monitored and confirmed by Western blot using mouse anti-ILK (BD Pharmigen #611802, 
1:1000). In this experiment, cells treated with control viral DNA (empty vector) are 
indicated as pLKO.1 and were used as a control. 
 
 
 
Statistical Analysis 
 
Results from at least four independent experiments were represented as mean   ±   SEM. 
Significant differences between groups were determined by one-way ANOVA followed by 
the Bonferroni post hoc test. When data normality was not verified, the Kruskal-Wallis test 
was used. 
Significance was set at p  <   0.05. All analysis was conducted using the software GraphPad 
Prism® 6.0 for Mac OSX (GraphPad Software, La Jolla CA). 
 
 
Results 
 
METH-Induced Loss of Viability in bEnd.3 Cells 
 
The viability of bEnd.3 cultures under different doses of METH and ALC was evaluated 
both by MTT and LDH assays. MTT results showed that mitochondrial activity was only 
affected by METH 1 mM, which was significantly reduced when compared to the control 
condition (p  <  0.05) (Fig. 1a ). ALC 1 mM added to the cells 30 min before METH 1 mM 
did not prevent the decrease in the viability of bEnd.3 cells. The results provided by the LDH 
assay confirmed the increased toxicity of METH 1 mM, which led to significant cell loss 
when compared to the control (p  <   0.001). In accordance with the data provided by the MTT 
assay, ALC 1 mM in combination with METH could not prevent bEnd.3 cell death (Fig. 1b). 
 
 
Fig 1 - Viability/cytotoxicity   assays:  a MTT assay, b LDH assay.  Confluent bEnd.3  cells  monolayers  were  treated  
with  ranging  concentration  of METH  and  ALC  1  mM.  a MTT  reduction  was  assessed  24  h  after treatment. b Cell 
death was measured by lactate dehydrogenase released on  the  bEnd.3  culture  medium  at the  same  time  
point.  Data represent mean  ±  SEM. Significant differences are marked as *p  <  0.05, **p  <  0.01, and * **p  <  0.001   
  
compared t o  t h e  c o n t r o l  g r o u p  ( as d e t e r m i n e d  b y ANOVA followed by the Bonferroni post hoc test) 
 
 
 
 
 
ALC Prevented the METH-Induced Loss of F-Actin 
Filaments Alignment 
 
F-actin filaments organization is characteristic of adhered and immobile endothelial cells. 
Using phalloidin to visualize F-actin, we observed a dose-dependent loss of stress fibers 
organization induced by METH (Fig. 2a ). This loss of organization was quantified through 
measuring the directionality of the filaments within the different conditions using a 
derivative of the original image (Fig. 2b ). In the control condition, F-actin filaments are 
mostly organized in a single orientation, with a high proportion of filaments aligned at the 
same direction. The filaments organization is progressively lost when cells are exposed to 
increasing doses of METH, as evidenced through directionality quantification (Fig. 2c ). 
Importantly, pretreatment with ALC 1 mM prevented the loss of organization induced by 
METH 1 mM as shown in Fig. 2d and e , where the majority of filaments were in a single 
direction (control vs METH 1 mM p  <  0.0001; ALC/METH 1 mM vs METH 1 mM, 
p  <  0.05). 
 
 
Fig 2 - F-actin filaments alignment.  Confluent bEnd.3 cells monolayers were treated with METH 0.5 and 1 mM doses 
according to the described procedures.  a Representative  images  are  shown  for  F-actin  filaments stained with Alexa 
Fluor® 488-Phalloidin and nuclei labeled with DAPI, after   METH   exposure.   The m e a n    histogram   for  each   
condition   is represented below the respective image. b Changes on F-actin filaments alignment  were analyzed  
  
by the Directionality  plugin  of Fiji Software, using  the  local  gradient  orientation  method  to  derive  the  
image.  c Proportion of actin filaments in a preferential direction after METH exposure. d F-actin filaments 
stained with Alexa Fluor® 488-Phalloidin and  labeled  with  DAPI,  when  cells  were  pretreated  with  ALC  1  
mM before METH exposure. The mean histogram for each condition is represented below the respective image. 
e Proportion of actin filaments in a preferential direction in cells treated with ALC 1 mM before METH exposure. 
Data represent mean  ±  SEM. ***p  <  0.001 compared to control group; ▽p  <  0.05 compared to METH 1 mM 
(as determined by ANOVA followed by the Bonferroni post hoc test) 
 
 
ALC Prevented the METH-Induced Loss and 
Redistribution of Claudin-5 
 
METH-induced changes in claudin-5 were previously reported [ 3 , 9 ,10 ]. Here, we aimed 
to assess the effect of ALC 1 mM in preventing these changes. Indirect immunofluorescence 
results showed that while in control conditions, claudin-5 is localized in the cellular 
membrane, after METH-exposure claudin-5 is also present in the cytoplasm (Fig. 3a and b 
). The ratio membrane/cytoplasm for claudin-5 localization is significantly decreased when 
cells are exposed for 24 h to METH (p  <   0.0001 for both METH 0.5 and 1 mM) compared 
to the control (Fig. 3b ). In addition, the total amount of claudin-5 was also significantly 
decreased after exposure to METH, as shown by Western 
blot analysis (p  <   0.01 for both METH 0.5 mM and 1 mM, compared to the control, Fig. 3c 
). To confirm the impact of METH on claudin-5 distribution, we performed a subcellular 
fractionation analysis, which confirmed an increase of cytoplasmatic claudin-5 content in 
cells treated with METH 1 mM (p  <   0.01, Fig. 3d ). 
 
 
  
 
Fig 3 - Claudin-5 decrease and redistribution. Confluent bEnd.3 cells monolayers were treated with METH 0.5 and 1 
mM, with or without ALC 1 mM or BB-94 10 nM. a Immunofluorescence representative images stained for 
claudin-5 and nuclei (DAPI). b Plot intensity profile for claudin-5 immunofluorescence  obtained  by  drawing  a  
straight  line  in  each  cell, always at the same position (Fiji Software), which enables to calculate the ratio between 
membrane and cytoplasm pixel intensity. (c) Total amount of claudin-5 determined by Western blot, mean 
ratio for each condition are represented.  (d)  Claudin 5 quantification after  subcellular fractionation of the 
cytoplasmatic and membranar portions.  Data represent mean  ±  SEM.  Significant differences are marked as 
*p  <  0.05; **p  <  0.01, and ***p  <  0.001 compared t o  control; ▽▽▽p  <  0.001 and ▽p  <  0.05 compared t o  the 
respective M E T H  dose  (as determined b y  ANOVA followed by the Bonferroni post hoc test)  
 
Aiming to evaluate the ability of ALC to prevent the METH-induced redistribution of 
claudin-5, we treated cells with ALC 1 mM. The redistribution of claudin-5 after METH 
exposure was partially prevented when ALC 1 mM was used, as shown by 
immunofluorescence images (Fig. 3a ) for both doses (METH 0.5 mM vs control p  <  0.001, 
METH 1 mM vs control p  <  0.05, Fig. 3b ). Total claudin-5 quantification by Western blot 
also evidenced a protective effect of ALC, although significance was only reached for METH 
1 mM dose (p  <   0.05, Fig. 3c ). When the quantification was performed separately in both 
subcellular fractions, significance for the protective effect of ALC was not achieved 
(p  =   0.22). 
 
METH did not Affect Occludin and ZO-1 
 
  
We investigated also the effect of METH exposure in ZO-1 and occludin. In our in vitro 
model, METH failed to induce any significant change in occludin or ZO-1, both when 
evaluated by immunofluorescence (Fig. 4a and d) or Western blot (Fig. 4b and e). To further 
confirm this, we performed an evaluation by subcellular fractionation, where occludin levels 
on the membrane and cytoplasmic fractions were shown to be unaltered after METH or 
ALC treatment (Fig. 4c ). 
 
 
Fig 4 - METH effects on occludin and Zonnula ocludens-1.  Confluent bEnd.3 cells monolayers were treated with 
METH 0.5 and 1 mM, with or without the pretreatment with ALC 1 mM. a Immunofluorescence representative 
images stained for occludin nuclei (DAPI). b Total amount of occludin determined by Western blot. c Occludin 
quantification after subcellular fractionation of the cytoplasmatic and membranar portions; ZO-1. d 
Immunofluorescence representative images stained for ZO-1 and nuclei (DAPI).  e  Total  amount  of  ZO-1  
determined  by  Western  blot.  Data represent mean  ±  SEM. No significant differences were observed (as 
determined by ANOVA followed by the Bonferroni post hoc test) 
 
 
 
ALC Prevented METH-Induced MMP-9 Activity 
 
As activation of MMPs is a common mechanism of BBB leakiness, we investigated also if 
  
the translocation of claudin-5 mechanism could be linked to METH-triggered MMPs 
activation. To understand if both MMP-2 and MMP-9 gelatinases were triggered by METH, 
gelatinolytic assays were performed. Our results show that MMP-9 release to the medium 
was increased by both METH 0.5 mM and 1 mM (Fig. 5a ). The increased activity was 
observed for METH 0.5 mM 12 h postexposure (p  <  0.05) and 16 h postexposure for METH 
1 mM (p  <   0.05, Fig. 5a ). This effect was higher at 24 h (p  <  0.001 for METH 0.5 mM and 
p  <  0.01 for METH 1 mM vs control). MMP-2 activity was not significantly affected by 
METH exposure (data not shown).  
 
 
 
Fig 5 - METH-triggered M M P -9 a c t i v i t y .  Confluent  bEnd.3  cells  monolayers were  treated  with  METH  0.5  
and  1  mM  and  cells;  the  medium  was collected  for  determination  of  gelatinases  activity.  a Graphic 
representation  of MMP-9 activity in culture mediums  collected  at 3, 6, 12, 16, 20, and 24 h after exposure 
to 0.5 mM METH (upper left) and 1 mM METH (upper right). b Zymography was performed to assess the 
effect of ALC 1 mM and BB-94 10 nM pretreatment on METH-induced MMP-9   activity   at   24   h.   Data   
represent   mean  ±  SEM.   Significant differences   are   marked   as   *p  <  0.05;   **p  <  0.01,   and   ***p  <  0.001 
compared to the control; ▽p  <  0.05, ▽▽p  <  0.01, and ▽▽▽p  <  0.001 compared to the respective METH-dose 
treated cells (as determined by ANOVA followed by the Bonferroni post hoc test) 
 
To test the effect of ALC at the MMP-9 level, we evaluated the release of this gelatinase in 
  
the presence of ALC added before METH exposure. As represented in Fig. 5b , ALC 1 mM 
was effective in preventing the activation of MMP-9 both for METH 0.5 and 1 mM (p  <   0.01 
for both METH doses vs control). The broad spectrum MMP inhibitor BB-94 was also 
assayed resulting in the expected inhibition of the METH-triggered MMPs activity (p  <   0.05 
for METH 0.5 mM and p  <  0.001 for METH 1 mM vs control, Fig. 5b ). Importantly, ALC 
inhibition of MMPs activity was not significantly different from that achieved with BB-94 
(p  >   0.9999). 
 
 
Next, we tested if the inhibition of MMPs activity would have an impact at the level of TJs. 
We added the MMP inhibitor BB-94 to the bEnd.3 cell culture before METH treatment and 
evaluated the distribution of claudin-5 by immunofluorescence analysis. As depicted in Fig. 
3a and quantified in Fig. 3b , inhibition of MMPs activity reduced METH-induced 
translocation of claudin-5 to the cytoplasm, as evidenced by the ratio membrane/cytoplasm 
for claudin-5 localization (p   <  0.001 for both METH doses vs control, Fig. 3b ). These results 
confirm that METH-induced translocation of claudin-5 is promoted by METH-triggered 
activation of MMPs, which was previously shown to have a crucial role in TJ degradation 
in other pathologic conditions. 
Importantly, at this level, the effect of BB-94 was similar to that of ALC (p  =  0.14). 
 
 
ALC Prevented ILK Expression Induced by METH 
 
Since ILK increased expression has been reported to increase MMP-9 activation, we 
investigated the impact of METH on ILK expression in bEnd.3 cells. Our results show that 
METH treatment induced a significant increase in ILK expression (p  <   0.05, METH vs 
control), which was totally prevented when ALC was added to the medium 30 min before 
METH exposure (p  <   0.05, METH vs ALC/METH), (Fig. 6a ). To our knowledge, the action 
of METH over ILK expression was never reported. Likewise, the preventive effect of ALC 
at this level is also a new and exciting feature for this compound. 
 
 
  
 
Figura 6 - ALC prevented METH-induced ILK i n c r e a s e d  e x p r e s s i o n .  Confluent bEnd.3 cells monolayers 
were treated with METH 1 mM with or without 1 m M  A L C .  a  Graphic  representation   of  the  total  amount  
of  ILK expression  24  h  after  METH  treatment  for  each  condition,  significant differences  are marked as 
*p  <  0.05  compared  to the control and ▽p  <  0.01 compared  to METH treatment.  b ILK silencing  in bEnd.3 
cells at 6 days of infection (**p  <  0.01 and ***p  <  0.0001, compared to the respective  non-silenced  cells,  
pLKO.1).  c  Zymography  performed  in bEnd.3 culture medium after METH and/or ALC treatment in ILK 
knockdown cells (KD ILK) and control cells (pLKO.1) (***p  <  0.001 for pLKO.1   vs   pLKO.1/METH,   ▽▽▽
p  <  0.001   for   KD   ILK   vs   KD ILK/IviE1H and V'V'p<O.Ol for pLKO.l  vs KD ILK/IviE1H and pLKO.liALCME1H).   
Data   represent    mean ±SEM.   Ali   significant differences were determined b y  ANOVA followed by the 
Bonfen·oni post hoc test 
 
 
ILK Silencing Prevented METH-Triggered MMP-9 
Activity 
 
 
  
Six days after infection, ILK silencing was completed (∼90 %) in endothelial cells as shown 
in Fig. 6b (p  <  0.001, KD ILK vs pLKO.1). When analyzed by zymography (Fig. 6c ), 
bEnd.3 cells treated with METH showed significantly higher levels of activated MMP-9 
than those where ILK was knockdown (p  <   0.001, pLKO.1/METH vs KD 
ILK/METH). Therefore, our results show that cells lacking ILK fail to respond to METH 
by increasing MMP-9 activity. As reported above, ALC was able to prevent the METH-
induced activation of MMP-9 (p  <  0.01 for pLKO.1/METH vs pLKO.1/ALCMETH). In 
addition, the action of ALC/METH in KD ILK cells is not different from the action of METH 
in these cells (p  >  0.9999 for KD ILK/METH vs KD ILK/ALCMETH), showing that ILK 
may be a target for ALC action. 
 
 
Discussion 
 
It is commonly accepted that MMP-induced leakiness at the BBB is a critical event for the 
development of several neurological diseases. In the present study, we provide evidence that 
ALC is able to prevent the METH-triggered activation of MMP-9 via ILK increased 
expression, preventing changes in F-actin arrangement and claudin-5 redistribution. To our 
knowledge, this is the first time that ALC is shown to prevent MMP-associated disruption 
of TJ and F-actin alignment, which is expected to contribute to maintain the BBB integrity. 
 
 
In healthy endothelial cells, F-actin is organized along the cell axis into bright oriented 
bundles, forming aligned filaments that promote traction forces, adhesion, and maintain the 
stability of cell morphology [ 44 ]. 
METH impact on actin filaments was observed in previous studies that reported either actin 
depolymerization, altered cell shape, local accumulation of condensed actin, or disruption 
of the F-actin parallel strands, leading to compromised TJ function [ 14 , 26 , 45 ]. In our 
study, METH exposure led to a dramatic loss of F-actin integrity concomitant with claudin-
5 redistribution and decreased expression. In endothelial cells, these events may lead to loss 
of adhesion and/or relevant restructuration of the endothelium, thus contributing to increase 
METH neurotoxicity. Interestingly, although METH-induced internalization of both claudin 
and occludin through endocytosis was previously seen to be concomitant with TJ 
fragmentation and gap formation [ 3 , 13 , 14 ], the functional significance of such 
translocation remains unclear, since it can occur also in the absence of BBB structural 
changes [ 15 ]. As the anchoring protein ZO-1 and the transmembrane protein occludin are 
physically linked to the actin filaments, some authors have hypothesized that actin 
depolymerization could be secondary to the loss of these binding interactions. METH impact 
on ZO-1, however, is not consensual, and similarly to what we report here, other authors 
also could not verify any changes in this particular protein [ 3 , 10 ]. 
Importantly, our work was the first to report ALC protection over METH-induced changes 
in TJ function, since a pretreatment with 1 mM ALC was effective in preventing the METH-
  
induced loss of actin alignment, as well as claudin-5 loss and translocation to the cytoplasm. 
The action of ALC at the cytoskeleton level is poorly explored, but previous in vitro studies 
have shown that ALC promotes microtubule stabilization which can render the cells more 
resistant to insults [ 30 ]. 
 
 
Different mechanisms have been proposed for the lack of BBB tightness after METH 
exposure [ 3 , 4 , 10 , 11 , 13 , 15 ]. Among those, the activation and expression of MMPs, a 
common mechanism of BBB leakiness, was often referred after METH exposure [ 4 , 6 , 9 ]. 
Based on previous reports where L-carnitine was seen to decrease glomerular sclerosis and 
interstitial fibrosis after cisplatin treatment, by reducing MMP-9 activity [ 46 ], and ALC 
administration was shown to ameliorate MMP-related dystrophy [ 47 ], we hypothesized that 
ALC could prevent METH-induced MMPs activity contributing this way to maintain the 
integrity of the endothelial monolayer. Increased MMP-9 activity after METH exposure was 
previously reported in brain regions associated to the reward system [ 6 , 9 ]. MMPs are 
proteolytic enzymes involved in the remodeling and cleavage of the extracellular matrix 
known to degrade TJ proteins. Our zymography results show that both METH 0.5 and 1 mM 
doses triggered the activity of MMP-9, but not of MMP-2. 
This is in accordance with former in vivo studies that reported a rapid transient increase in 
striatal MMP-9 expression and activity after repeated low doses of METH, which was 
associated with increased degradation of extracellular matrix components and increased 
BBB permeability [ 4 , 6 , 9 , 48 ]. As hypothesized, ALC 1 mM was able to prevent MMP-
9 increased activity in cells exposed to METH, which prevented changes on F-actin 
alignment and reduced claudin-5 redistribution, contributing to maintain the integrity of the 
endothelial cytoskeleton. These results open new insights into ALC therapeutic use. 
 
 
Another possible mechanism for METH-induced damage at the BBB level is associated to 
increased production of ROS by endothelial cells [ 3 , 10 , 13 , 29 ]. In a former study, it was 
proposed that increased oxidative stress in METH-treated endothelial cells could lead to 
cytoskeleton rearrangement and TJ redistribution through RhoA activation [ 10 ]. Modulation 
of RhoGTPases by METH has been reported showing that RhoA, Rac, or Cdc42 can be 
modulated by METH, impacting the endothelial barrier [ 10 , 13 , 14 ]. Constitutive activation 
of RhoGTPases was associated with TJ endocytosis and stress fibers assembly and 
reorganization [ 14 , 49 , 50 ]. Rho-associated coiled-coil-containing kinases (ROCK) are 
important cytoskeleton regulators through downstream modulation of actin, myosin, and 
associated proteins [ 10 , 49 – 51 ]. Previous studies have shown the involvement of the 
Rho/ROCK pathway on actin reorganization and verified that ROCK inhibition was able to 
block actin disruption [ 50 , 52 ]. Aiming to evaluate the role of ROCK on METH-induced 
structural damage, we used the ROCK selective inhibitor fasudil. However, ROCK inhibition 
did not prevent METH-induced disruption of F-actin organization and led to a highly 
disturbed structural pattern (Online Resource 1 ). The influence of RhoGTPases activation 
and/or inactivation on TJ function is ambiguous. In Madin-Darby canine kidney (MDCK) 
epithelial cells expressing constitutively active or dominant-negative RhoA, Rac1, or Cdc42, 
it was shown that activation, as well as inactivation, of each GTPase resulted in increased 
  
paracellular permeability and dramatic reorganization of the F-actin cytoskeleton and TJ 
proteins [ 49 ], evidencing that Rho GTPases in epithelial junctions may regulate the barrier 
function through distinct mechanisms. 
 
 
Several possible mechanisms were proposed for METH-triggered MMP-9 activity, 
involving different signaling cascades depending on stimulus, cell type, and MMP isoform 
[ 6 , 53 ]. Mechanisms related with METH-induce glutamate [ 6 ] or dopamine [ 54 ] release 
are plausible in vivo, but not feasible in our bEnd.3 model. Increased phosphorylation of 
p38, JNK1/2, and/or ERK1/2 proteins leading to higher transcription of MMPs was also 
suggested [ 4 , 47 , 53 ]. 
Importantly, JNK1/2 and p38 were both reported to suffer increased phosphorylation after 
METH exposure in vivo [ 11 ] and decreased phosphorylation after ALC administration [ 47 
]. However, in the present study, we could not observe increased MMP transcription as a 
consequence of METH exposure (Online Resource 2 ), suggesting that METH-triggered 
MMP-9 activity may occur through posttranslational processes. 
 
 
Cell adhesion to the extracellular matrix is an important process controlling cell shape 
change, migration, proliferation, survival, and differentiation. Recent studies have revealed 
that cytoplasmic integrin- linked kinase (ILK) and its interactive proteins play important 
roles in these processes [ 55 ]. ILK is directly binded to the cytoplasmic domains of β1 
integrin and connects integrins to the actin cytoskeleton by interacting directly with several 
proteins such as paxillin and parvin, thus, coordinating actin organization [ 55 , 56 ]. There 
is evidence that ILK expression stimulates MMP-9 activation, whereas ILK silencing 
inhibits invasion in several carcinomas [ 56 , 57 ]. In normal epithelial cells, the loss of cell–
cell adhesion is the hallmark of ILK overexpression, due to the E-cadherin downregulation 
and nuclear translocation [ 58 ]. ILK overexpression and clustering results in the activation 
of a variety of intracellular signaling processes such as Akt phosphorylation and GSK-3 
inhibition, which lead to the activation of the transcription factor AP-1 resulting in the 
MMP-9 potentiation [ 55 , 57 ]. In the present work, we show that METH-triggered activation 
of MMP-9 is mediated by ILK overexpression, which, to our knowledge, was never shown 
before. Although it was suggested that ILK may upregulate MMP-9 by promoting MMP-9 
overexpression, as already mentioned, we failed to observe METH-induced increased 
transcription of MMP-9 (Online Resource 2 ). However, other authors have also reported 
ILK-dependent increased MMP-9 activity in the absence of significant changes in its 
expression, suggesting that under ILK regulation, various pathways may be involved [ 58 ]. 
 
 
BBB impairment after METH exposure may exacerbate drug neurotoxicity and may 
contribute to the long-term neurodegeneration and cognitive deficits frequently reported. 
This may occur by increased extravasation of neurotoxic proteins and pro-inflammatory 
molecules across the barrier, as well as deficits in both transcellular and paracellular 
transports [ 7 , 15 ]. We show also that ALC was effective in preventing the increased 
expression of ILK, thus preventing MMP-9 activation and preserving actin structure and TJ 
function. The present results support the potential of ALC in preserving the BBB integrity, 
which was already demonstrated in vivo, since it was shown that alcohol impairment on 
human brain endothelium is prevented by ALC treatment [ 28 , 29 ]. Of note, our results 
highlight ILK as a new target for ALC therapeutic use. The ongoing development of 
selective inhibitors of both MMP-9 and ILK as potential pharmacologic targets in several 
  
diseases may benefit from ALC investigation particularly in the oncology field, where 
increased activity of MMPs is long known to be associated with tumor invasion and 
metastatic potential [ 59 , 60 ]. 
 
 
Despite the protection obtained at the structural level, ALC was not able to prevent cell 
death and reduced viability in our bEnd.3 cultures exposed to METH 1 mM. In isolated 
endothelial cells, loss of viability under METH exposure can be associated with 
mitochondrial dysfunction caused by deficient antioxidant defense machinery accompanied 
by substantial lipid peroxidation, protein carbonylation, and increased ROS generation, 
which leads to disruption of the mitochondrial electrochemical gradient, impaired ATP 
synthesis, and energy deficits [for review, see 2 ]. In this scenario, cell death may arise as a 
consequence of METH-induced release of cytochrome c into the cytosol and resulting 
activation of caspase-mediated apoptotic pathways. The involvement of nitric oxide (NO) 
and peroxynitrite in METH-related apoptotic mechanisms has also been reported [ 61 ]. 
Moreover, it has been shown that, through ROS-signaling, METH can regulate the 
expression of AP-1, NF-κB, and AP-2 families that are crucial in controlling death and 
survival signals [for review, see 2 ]. Via JNK activation, ROS-signaling can also induce 
DNA strand break and base excision [ 62 ]. In addition, endothelial cells are important 
producers of several cytokines and release high amounts of interleukin-1 (IL-1) [ 63 ], which 
is known to be the major endogenous pyrogen [ 64 ]. Although we did not collect any data 
regarding METH-induced hyperthermia, changes in cellular morphology under 
METH exposure were shown to tightly correlate with hyperthermia and increased BBB 
permeability [ 65 ]. Noteworthy, we have shown in vivo that ALC neuroprotection over 
MDMA exposure is not related to the drug-induced thermal response [ 66 ]. We have also 
shown that in vivo ALC prevents DNA damage and carbonyl formation, but not lipid 
peroxidation [ 66 ]. Using a human endothelial cell line, other authors demonstrated that 
ALC prevents METH-induced loss of cell viability under glucose deprivation [ 67 ]. In such 
conditions, ALC may increase the availability of acyl-CoA to the citric acid cycle 
counteracting the decreased pyruvate dehydrogenase activity. However, under standard 
glucose levels, as in the present study, ALC protection against METH-induced cell loss was 
not shown. As such, we reason that the rate of cell loss observed for METH 1 mM is probably 
due to increased ROS/RNS-signaling at the mitochondrial level, through the activation of 
pathways that cannot be regulated by ALC. 
 
 
Conclusion 
 
In summary, we showed that in endothelial cells, exposure to METH led to disruption of 
actin filaments concomitant with claudin-5 translocation to the cytoplasm. These events 
seem to be mediated by MMP-9 activation in association with ILK overexpression and may 
lead to TJ dysfunction and BBB increased permeability. Our work was the first to assess the 
role of ALC as a neuroprotective agent over METH-induced damage via MMP-9 activity. 
  
Pretreatment with ALC prevented METH-induced activation of MMP-9, preserving claudin-
5 location and the structural arrangement of the actin filaments (Fig. 7 ). Our results highlight 
ILK as a nouvelle target for ALC therapeutic use, adding to the list of ALC benefits in 
several neurologic conditions. Of note, this may be of particular interest in the oncology field 
due to the close relation between MMP-9 activity and metastatic events. 
 
Fig. 7 
 
Schematic representation of the ALC protective role over the molecular events triggered by 
METH in endothelial cells. Exposure to METH in bEnd.3 l e a d s  t o  d i s r u p t i o n    of t h e  
a c t i n  f i l a m e n t s    arrangement   and claudin-5 translocation to the cytoplasm (and 
decreased expression). We show that these events are mediated by MMP-9 activation in 
association with ILK overexpression and may lead to tight junction dysfunction and increased    
BBB    permeability.    Pretreatment    with    ALC    prevented METH-induced activation of 
MMP-9 and preserved the arrangement of actin filaments and claudin-5 distribution. Our 
results highlight ILK as a nouvelle target for the ALC therapeutic use 
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